About Medicoremedies
Medicoremedies is a publicly listed company founded in 1994. Pharmaceutical formulations are manufactured, emphasizing anti-infectives and therapeutic drugs. The company has 70 employees. Its Indian entity Medico Remedies Limited reported revenue of ₹212 Cr. Medicoremedies offers products and services including Anti-Infectives and Vitamins and Supplements. Its focus areas include Traditional Pharmaceuticals.
Company details
Operations in the pharmaceutical sector are centered on the production and distribution of formulations, including beta-lactams, cephalosporins, antimalarials, antiretrovirals, anti-ulcer drugs, antacids, vitamins, haematinics, supplements, NSAIDs, antihistamines, anti-diabetics, cardiovascular drugs, diuretics, anti-epileptics, combination kits, syrups, creams, and gels. Focus is placed on diverse therapeutic areas, with capabilities extending to marketing across multiple segments.
- Employees 70
- Stage Public
- SectorsHealthcare
- Website medicoremedies.com
- Legal Name Medico Remedies Limited
- Date of Incorporation 18 Mar, 1994
- Jurisdiction Mumbai, Maharashtra, India
- Market Cap₹155 Cr
MEDICO · NSE
- Share Price₹18.44
-1.23% today
- Revenue₹206 Cr
FY 2025-26 · +36.7% YoY
- EBITDA₹17.03 Cr
Margin 8.2%
- Net Profit₹13.10 Cr
FY 2025-26 · +29.7% YoY
- P/E (TTM)11.5x
P/B 2.0x
- ROE19.0%
ROCE 23.2%
- Debt / Equity0.24
Interest cover 13.0x
- Employee Count70
Associated legal entities of Medicoremedies
Medicoremedies operates through Medico Remedies Limited, a listed company (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Medico Remedies Limited Listed CIN L24230MH1994PLC077187 | Active | 18 Mar 1994 | Mumbai, Maharashtra | ₹212 Cr | 70 | 12 | View details |
Products & Services of Medicoremedies
Medicoremedies offers a comprehensive portfolio of products and services, including Anti-Infectives and Vitamins and Supplements.
Formulations for treating infections are produced by the company.
Vitamins, haematinics, and other supplements are manufactured and marketed for therapeutic uses.
Board of directors of Medico Remedies Limited (Medicoremedies)
Medico Remedies Limited is the primary company behind Medicoremedies. The board of Medico Remedies Limited currently have 10 directors; the longest-serving is Haresh Kapurlal Mehta, appointed in 1994. 6 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Haresh Kapurlal Mehta DIN 01080289 | Whole-time director | 18 Mar 1994 | 32 yrs 7 mo | Medico Remedies Limited |
| Rita Haresh Mehta DIN 01080344 | Director | 08 Dec 1999 | 26 yrs 11 mo | Medico Remedies Limited |
| Harshit Haresh Mehta DIN 05144280 | Managing Director | 14 Dec 2011 | 14 yrs 11 mo | Medico Remedies Limited |
| Rishit Hareshbhai Mehta DIN 07121224 | Whole-time director | 12 Mar 2015 | 11 yrs 8 mo | Medico Remedies Limited |
| Deepak Maganlal Vekaria DIN 07945925 | Director | 25 Sep 2017 | 9 yrs 1 mo | Medico Remedies Limited |
| Bharat Nathalal Rathod DIN 07947531 | Director | 25 Sep 2017 | 9 yrs 1 mo | Medico Remedies Limited |
| Deepesh Rajesh Shah DIN 07321104 | Director | 22 Apr 2022 | 4 yrs 6 mo | Medico Remedies Limited |
| Kunal Tushar Vora DIN 10741410 | Director | 13 Aug 2024 | 2 yrs 3 mo | Medico Remedies Limited |
| Anuj Kishore Mody DIN 08835177 | Director | 12 Nov 2024 | 2 yrs | Medico Remedies Limited |
| Maheshkumar Rameshchandra Darji DIN 11220436 | Director | 30 Jul 2025 | 1 yr 3 mo | Medico Remedies Limited |
IPO & Listings of Medicoremedies
Medicoremedies is a publicly listed company on the NSE with ticker symbol MEDICO in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date26 May 2022
- Listed onNSE: MEDICO
- Listed entityMedico Remedies Ltd.
- Exchange sectorHealth technology
Financials of Medicoremedies
Exchange-reported figures of Medico Remedies Limited, the listed company behind Medicoremedies (NSE: MEDICO).
Financial Highlights
FY 2025-26 · StandaloneRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 206 | 151 | 145 | 140 | 121 | 122 | 88.64 |
| Revenue growth | +36.7% | +4.2% | +3.2% | +16.1% | -1.1% | +38.1% | - |
| EBITDA | 17.03 | 15.01 | 12.91 | 9.62 | 7.34 | 5.24 | 2.84 |
| EBITDA margin | +8.3% | +9.9% | +8.9% | +6.9% | +6.1% | +4.3% | +3.2% |
| Profit before tax | 18.06 | 13.51 | 11.34 | 10.10 | 6.49 | 3.70 | 2.22 |
| Net profit | 13.10 | 10.10 | 8.29 | 7.24 | 4.85 | 2.59 | 1.64 |
| Net profit margin | +6.4% | +6.7% | +5.7% | +5.2% | +4.0% | +2.1% | +1.9% |
| EPS (₹) | 1.58 | 1.22 | 1.00 | 0.87 | 2.90 | 6.24 | 3.93 |
| Balance sheet | |||||||
| Total assets | 94.38 | 76.67 | 60.42 | 53.96 | 49.29 | 47.61 | 43.74 |
| Net worth | 75.48 | 62.47 | 52.37 | 43.85 | 36.58 | 32.46 | 29.87 |
| Total debt | 18.91 | 13.84 | 8.05 | 9.77 | 12.60 | 15.05 | 13.87 |
| Cash & bank | 1.91 | 1.09 | 0.18 | 0.91 | 2.34 | 2.83 | 1.42 |
| Net working capital | 68.06 | 52.10 | 36.72 | 29.96 | 29.46 | 29.57 | 25.33 |
| Cash flow | |||||||
| Cash from operations | 5.87 | 4.89 | 2.44 | 8.17 | 5.86 | (11.31) | 0.97 |
| Cash from investing | (4.51) | (3.46) | (2.68) | (6.60) | (1.76) | (16.96) | (3.08) |
| Cash from financing | (0.55) | (0.52) | (0.49) | (1.82) | (5.77) | 18.28 | 2.60 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 73.97 | 69.40 | 56.81 | 58.68 | 52.64 | 38.25 | 41.30 | 39.49 |
| Revenue growth (YoY) | +40.5% | +81.4% | +37.6% | +48.6% | +33.8% | +24.2% | - | - |
| Other income | 1.31 | 1.17 | 2.87 | 0.68 | 1.72 | 0.66 | 0.29 | 1.43 |
| Total expenses | 70.81 | 66.10 | 49.66 | 54.35 | 49.92 | 35.43 | 34.64 | 36.38 |
| EBITDA | 3.16 | 3.30 | 7.15 | 4.33 | 2.72 | 2.82 | 6.66 | 3.11 |
| EBITDA margin | +4.3% | +4.8% | +12.6% | +7.4% | +5.2% | +7.4% | +16.1% | +7.9% |
| Depreciation | 0.75 | 0.72 | 0.80 | 0.79 | 0.73 | 0.77 | 0.77 | 0.76 |
| Interest | 0.45 | 0.41 | 0.90 | 0.39 | 0.24 | 0.28 | 0.49 | 0.28 |
| Profit before tax | 3.27 | 3.34 | 8.32 | 3.83 | 3.47 | 2.43 | 5.69 | 3.50 |
| Tax | 0.89 | 0.82 | 2.47 | 0.96 | 0.90 | 0.62 | 1.36 | 0.88 |
Financial Statements
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 73.97 | 69.40 | 56.81 | 58.68 | 52.64 | 38.25 | 41.30 | 39.49 |
| Revenue growth (YoY) | +40.5% | +81.4% | +37.6% | +48.6% | +33.8% | +24.2% | - | - |
| Other income | 1.31 | 1.17 | 2.87 | 0.68 | 1.72 | 0.66 | 0.29 | 1.43 |
| Total expenses | 70.81 | 66.10 | 49.66 | 54.35 | 49.92 | 35.43 | 34.64 | 36.38 |
| EBITDA | 3.16 | 3.30 | 7.15 | 4.33 | 2.72 | 2.82 | 6.66 | 3.11 |
| EBITDA margin | +4.3% | +4.8% | +12.6% | +7.4% | +5.2% | +7.4% | +16.1% | +7.9% |
| Depreciation | 0.75 | 0.72 | 0.80 | 0.79 | 0.73 | 0.77 | 0.77 | 0.76 |
| Interest | 0.45 | 0.41 | 0.90 | 0.39 | 0.24 | 0.28 | 0.49 | 0.28 |
| Profit before tax | 3.27 | 3.34 | 8.32 | 3.83 | 3.47 | 2.43 | 5.69 | 3.50 |
| Tax | 0.89 | 0.82 | 2.47 | 0.96 | 0.90 | 0.62 | 1.36 | 0.88 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 206 | 151 | 145 | 140 | 121 | 122 | 88.64 |
| Revenue growth | +36.7% | +4.2% | +3.2% | +16.1% | -1.1% | +38.1% | - |
| Other income | 5.93 | 2.69 | 2.13 | 3.95 | 2.03 | 1.03 | 2.10 |
| Total expenses | 189 | 136 | 132 | 131 | 114 | 117 | 85.80 |
| Employee cost | 5.71 | 4.70 | 5.92 | 5.68 | 5.41 | 4.50 | 3.83 |
| EBITDA | 17.03 | 15.01 | 12.91 | 9.62 | 7.34 | 5.24 | 2.84 |
| EBITDA margin | +8.3% | +9.9% | +8.9% | +6.9% | +6.1% | +4.3% | +3.2% |
| Depreciation | 3.09 | 3.03 | 2.88 | 2.72 | 2.22 | 1.65 | 1.66 |
| Interest | 1.81 | 1.16 | 0.82 | 0.75 | 0.66 | 0.92 | 1.06 |
| Profit before tax | 18.06 | 13.51 | 11.34 | 10.10 | 6.49 | 3.70 | 2.22 |
| Tax | 4.95 | 3.41 | 3.05 | 2.86 | 1.67 | 1.11 | 0.58 |
| Net profit | 13.10 | 10.10 | 8.29 | 7.24 | 4.85 | 2.59 | 1.64 |
| Net profit margin | +6.4% | +6.7% | +5.7% | +5.2% | +4.0% | +2.1% | +1.9% |
| EPS (₹) | 1.58 | 1.22 | 1.00 | 0.87 | 2.90 | 6.24 | 3.93 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 16.60 | 16.60 | 16.60 | 16.60 | 16.60 | 4.15 | 4.15 |
| Reserves & surplus | 58.88 | 45.87 | 35.77 | 27.25 | 19.98 | 28.31 | 25.72 |
| Shareholders' funds (net worth) | 75.48 | 62.47 | 52.37 | 43.85 | 36.58 | 32.46 | 29.87 |
| Secured loans | 17.15 | 12.75 | 5.90 | 7.85 | 10.37 | 12.79 | 13.04 |
| Unsecured loans | 1.76 | 1.09 | 2.15 | 1.92 | 2.23 | 2.26 | 0.83 |
| Total debt | 18.91 | 13.84 | 8.05 | 9.77 | 12.60 | 15.05 | 13.87 |
| Total liabilities | 94.38 | 76.67 | 60.42 | 53.96 | 49.29 | 47.61 | 43.74 |
| Assets | |||||||
| Gross block | 44.41 | 42.71 | 41.35 | 38.80 | 32.39 | 28.87 | 24.36 |
| Net block | 20.41 | 21.29 | 21.50 | 21.83 | 18.03 | 15.31 | 12.54 |
| Capital work in progress | 2.57 | 0.36 | 0.00 | 0.07 | 0.00 | 0.00 | 2.28 |
| Investments | 1.89 | 1.65 | 1.57 | 1.27 | 0.00 | 1.17 | 0.15 |
| Inventories | 30.02 | 26.73 | 16.34 | 19.70 | 18.11 | 14.55 | 18.26 |
| Sundry debtors | 81.99 | 57.18 | 49.63 | 36.09 | 30.39 | 27.42 | 23.89 |
| Cash & bank balances | 1.91 | 1.09 | 0.18 | 0.91 | 2.34 | 2.83 | 1.42 |
| Loans & advances | 13.16 | 10.22 | 6.20 | 6.57 | 6.73 | 12.62 | 13.07 |
| Total current assets | 127 | 95.22 | 72.35 | 63.27 | 57.57 | 57.42 | 56.64 |
| Total current liabilities | 59.02 | 43.12 | 35.63 | 33.31 | 28.11 | 27.85 | 31.31 |
| Net working capital | 68.06 | 52.10 | 36.72 | 29.96 | 29.46 | 29.57 | 25.33 |
| Total assets | 94.38 | 76.67 | 60.42 | 53.96 | 49.29 | 47.61 | 43.74 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 1.09 | 0.18 | 0.91 | 1.17 | 2.83 | 0.00 | 0.16 |
| Net cash from operating activities | 5.87 | 4.89 | 2.44 | 8.17 | 5.86 | (11.31) | 0.97 |
| Net cash from investing activities | (4.51) | (3.46) | (2.68) | (6.60) | (1.76) | (16.96) | (3.08) |
| Net cash from financing activities | (0.55) | (0.52) | (0.49) | (1.82) | (5.77) | 18.28 | 2.60 |
| Net change in cash | 0.81 | 0.91 | (0.73) | (0.25) | (1.67) | (9.99) | 0.48 |
| Closing cash | 1.91 | 1.09 | 0.18 | 0.91 | 2.34 | 2.83 | 1.42 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +36.7% | +4.2% | +3.2% | +16.1% | -1.1% | +38.1% | - |
| EBITDA growth | +13.5% | +16.3% | +34.2% | +31.1% | +40.1% | +84.5% | - |
| PBT growth | +33.7% | +19.1% | +12.3% | +55.6% | +75.4% | +66.7% | +2.3% |
| Net income growth | +29.7% | +21.8% | +14.5% | +49.3% | +87.3% | +57.9% | - |
| Revenue CAGR (3Y) | +13.7% | +7.6% | +5.8% | +16.6% | +7.4% | +26.1% | +17.7% |
| EBITDA CAGR (3Y) | +21.0% | +26.9% | +35.1% | +50.2% | +38.6% | +14.5% | -8.4% |
| Profitability & leverage | |||||||
| Net income margin | +6.4% | +6.7% | +5.7% | +5.2% | +4.0% | +2.1% | +1.9% |
| Return on capital employed | +23.2% | +21.4% | +21.2% | +21.0% | +14.7% | +10.1% | +7.6% |
| Return on net worth | +19.0% | +17.6% | +17.2% | +18.0% | +13.9% | +8.3% | +5.6% |
| Debt / equity | 0.24 | 0.19 | 0.19 | 0.28 | 0.40 | 0.46 | 0.47 |
| Long-term debt / equity | 0.00 | 0.01 | 0.02 | 0.05 | 0.11 | 0.15 | 0.12 |
| Interest cover | 12.98 | 9.68 | 8.18 | 10.87 | 12.89 | 25.63 | 89.83 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 4.74 | 3.59 | 3.62 | 3.95 | 3.95 | 4.60 | 3.79 |
| Inventory turnover | 7.27 | 7.01 | 8.04 | 7.43 | 7.41 | 7.46 | 5.16 |
| Debtors turnover | 2.97 | 2.83 | 3.38 | 4.23 | 4.19 | 4.77 | 3.35 |
| EPS (₹) | 1.58 | 1.22 | 1.00 | 0.87 | 2.90 | 6.24 | 3.93 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 9.10 | 7.53 | 6.31 | 5.28 | 22.04 | 78.22 | 71.98 |
Web traffic of Medicoremedies
The website of Medicoremedies (medicoremedies.com) receives about 1.2K visits a month.
- Monthly visits1.2K
▼ 12.4% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Medicoremedies
Complete news archive for Medicoremedies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Medicoremedies
Medicoremedies was founded in 1994.
Medicoremedies has 70 employees.
The primary company behind Medicoremedies, Medico Remedies Limited, reported revenue of ₹212 Cr for FY 2026, up 37% year on year.
Operations in the pharmaceutical sector are centered on the production and distribution of formulations, including beta-lactams, cephalosporins, antimalarials, antiretrovirals, anti-ulcer drugs, antacids, vitamins, haematinics, supplements, NSAIDs, antihistamines, anti-diabetics, cardiovascular drugs, diuretics, anti-epileptics, combination kits, syrups, creams, and gels. Focus is placed on diverse therapeutic areas, with capabilities extending to marketing across multiple segments.
Medicoremedies offers Anti-Infectives and Vitamins and Supplements.
Yes, Medicoremedies is publicly traded on NSE under the ticker symbol MEDICO.
Medicoremedies operates through Medico Remedies Limited.
The legal entities of Medicoremedies currently have 11 directors, including Rita Haresh Mehta, Haresh Kapurlal Mehta, Harshit Haresh Mehta and others.